Better Health, Brighter Future for Rare

October 4, 2023


“I want to help bring forward medicines that are going to transform people’s lives.”

Dr. Daniel Curran leads Takeda Pharmaceutical’s efforts to unlock innovation and deliver transformative medicines in a variety of rare-disease areas. Dan embraces learning from, collaborating with, and meeting members of the rare disease community while helping produce treatments that result in better health and a brighter future for rare.

On This Episode We Discuss:

  • 2:02 How rare disease is defined at Takeda
  • 4:10 Rare disease units at Takeda
  • 5:23 How Takeda economically justifies half of their pipeline being rare disease drugs
  • 9:06 The price of rare disease drugs is too high
  • 12:15 Why rare disease efforts are often associated with hematology
  • 14:57 What Dr. Curran enjoys about leading Takeda’s rare genetics and hematology therapeutic unit
  • 16:42 Dr. Curran’s professional journey
  • 20:50 Takeda’s choice to support n-Lorem

Watch on YouTube:

Dr. Daniel Curran is the Head of the Rare Genetics and Hematology Therapeutic Area Unit (TAU) at Takeda Pharmaceuticals. In this role, he leads Takeda’s efforts to unlock innovation and deliver transformative medicines in the areas of rare immunology, rare hematology, lysosomal storage disorders, rare genetic and metabolic diseases. Previously, Dr. Curran served as Head of Takeda’s Center for External Innovation (CEI). In this role, he and his team diversified Takeda’s pipeline, completed approximately 150 transactions and invested $1.5 billion in capital in external relationships and investments over a three-year period. In addition, Dr. Curran led the Takeda-CiRA collaboration, a joint research program with Kyoto University’s Center for iPS Cell Research Application.

Prior to his role as Head of CEI, Dr. Curran led the corporate development group at Millennium: The Takeda Oncology Company and was a member of the executive management team. In that role, he oversaw the development and execution of corporate strategic business development initiatives, including licensing arrangements, acquisitions and a range of other transactions.

He has 20 years of pharmaceutical experience in business development, project leadership and development roles. Prior to Millennium, previous professional experiences include a business development role in the Product Planning and Acquisition group at DuPont Merck Pharmaceuticals.

Dr. Curran received an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School of the University of Pennsylvania and a B.S. in chemistry from King’s College.

About Takeda:

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline.


Hosted by: Dr. Stan Crooke.
Videographer: Jon Magnuson of Mighty One Productions.
Producers: Kim Butler, Colin Delaney, Kira Dineen, Jon Magnuson, Andrew Serrano and Amy Williford.

More from n-Lorem:

See what else we are up to on Twitter, Instagram, Facebook, Linked In, YouTube and our website, If you enjoy this episode, please rate and review us, as it helps others find our podcast. Questions/inquiries can be sent to [email protected].

Listen to our next interview:

We cannot do
this alone

Together we are changing the world—
one patient at a time

We hope that you join us on this journey to discover, develop and provide individualized antisense medicines for free for life for nano-rare patients. The ultimate personalized medicine approach – for free, for life.

We need your support

Join us on our Corps of Discovery of the mind and heart. Help us bring hope and potential help to nano-rare patients today. For free, for life.

Follow us on social for updates on our latest efforts